Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 2/20 | 0.73 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116948 | 0.84 | TCF4 (1.00) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL31253926 | 0.84 | TCF4 (1.00) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL14896438 | 0.84 | TCF4 (0.80) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL2896485 | 0.84 | MAPT (0.65) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL8369354 | 0.84 | TCF4 (0.80) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL16116951 | 0.83 | TCF4 (1.00) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL6981654 | 0.83 | TCF4 (0.78) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL16116946 | 0.81 | TCF4 (0.74) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL16119561 | 0.80 | LMNA (0.77) | TCF4CTNNB1POLBLMNASMN1; SMN2 | |
| SCHEMBL7313388 | 0.79 | PLAU (0.77) | TCF4CTNNB1POLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | TCF4 4515/4885CTNNB1 4000/4885POLB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.